Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Lifecore Biomedical (LFCR) over the last 14 years, with May 2025 value amounting to -$8.9 million.

  • Lifecore Biomedical's Gains from Investment Securities fell 7181.15% to -$8.9 million in Q2 2025 from the same period last year, while for May 2025 it was -$7.8 million, marking a year-over-year decrease of 325.38%. This contributed to the annual value of -$7.8 million for FY2025, which is 325.38% down from last year.
  • As of Q2 2025, Lifecore Biomedical's Gains from Investment Securities stood at -$8.9 million, which was down 444.97% from -$1.6 million recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical's Gains from Investment Securities peaked at $2.1 million during Q4 2024, and registered a low of -$8.9 million during Q2 2025.
  • Moreover, its 3-year median value for Gains from Investment Securities was $25,000 (2023), whereas its average is -$1.1 million.
  • Per our database at Business Quant, Lifecore Biomedical's Gains from Investment Securities spiked by 8,492.00% in 2024 and then crashed by 7,181.15% in 2025.
  • Over the past 5 years, Lifecore Biomedical's Gains from Investment Securities (Quarterly) stood at $84,000 in 2021, then spiked by 69.05% to $142,000 in 2022, then slumped by 82.39% to $25,000 in 2023, then skyrocketed by 8,492.00% to $2.1 million in 2024, then tumbled by 7,181.15% to -$8.9 million in 2025.
  • Its Gains from Investment Securities stands at -$8.9 million for Q2 2025, versus -$1.6 million for Q1 2025 and $2.1 million for Q4 2024.